Lp(a) ≥50 mg/dL: An Emerging Determinant of Valvular Risk and Evolving Role of Aspirin- Dr Rajesh B. Bhurkunde

The pattern of valvular heart disease in India is shifting. Degenerative tricuspid aortic stenosis now accounts for 58.1% of acquired isolated aortic stenosis (AS) cases (mean age 63.2 ± 8.8 years), with Indians developing calcific valvular disease nearly a decade earlier than Western populations. This shift highlights a critical opportunity for early risk identification and primary prevention before irreversible valvular damage occurs. As this early-onset cohort expands, aspirin is emerging as a potential preventive intervention — particularly in individuals with elevated lipoprotein(a), a genetically determined risk factor prevalent in 1 in 4 Indians. [1,2,3]

Why Are Indians at Disproportionately Higher Risk for Calcific Aortic Valve Disease?

India carries an outsized genetic and metabolic risk burden for premature valvular calcification. Elevated Lp(a), a stable, genetically determined lipid fraction, affects 25% of Indians, exceeding the global ~20% baseline. This genetic predisposition is compounded by pervasive lipid dysfunction: 49.9% dyslipidemia among 18–25 year-olds and 72.4% low HDL-C in adults aged ≥45 years. The convergence of high Lp(a) with widespread dyslipidemia creates a distinct risk phenotype for early-onset calcific valve disease-one that is largely invisible without proactive Lp(a) screening. [3,4,5]

What Makes Lp(a) a Causal Driver of Valvular Calcification — and Why Do Guidelines Now Emphasize Testing?

Through oxidized phospholipids and prothrombotic mechanisms, Lp(a) drives fibrocalcific deposition in valvular tissue, promoting platelet activation and inhibiting fibrinolysis — with genetic and prospective studies consistently supporting causal valvular associations. [6,7]L

The 2026 ACC/AHA dyslipidemia guidelines now recommend once-in-a-lifetime Lp(a) measurement, recognizing levels ≥50 mg/dL as a risk-enhancing factor for CVD, including CAVD. In India, the CSI and LAI have issued aligned recommendations for at-least-once lifetime Lp(a) testing, guidance that takes on particular urgency given early-onset valvular disease patterns in South Asian populations. Crucially, Lp(a) remains minimally modified by lifestyle and requires distinct risk stratification beyond standard lipid management. [2,8,9]

What Did the Landmark 2026 MESA Analysis Find About Aspirin and Aortic Valve Calcium?

The Multi-Ethnic Study of Atherosclerosis (MESA) provides the first prospective data on aspirin use across Lp(a) and LDL-C strata in 6,598 participants followed for incident aortic valve calcium (AVC) and severe aortic stenosis. Regular aspirin use (≥3 days/week) was associated with a strong, Lp(a)-dependent risk reduction: [10]

• Incident AVC risk: ~58% lower at Lp(a) ≥75 mg/dL (HR 0.42), rising to ~83% lower at Lp(a) ≥100 mg/dL (HR 0.17)

• Severe aortic stenosis risk: ~87% lower at Lp(a) ≥50 mg/dL (HR 0.13) and ~98% lower at Lp(a) ≥75 mg/dL (HR 0.02)

                                                                                  Figure 1: Aspirin, Lp(a), and Aortic Valve Calcium: Key Findings from the 2026 MESA Study

Critically, this benefit was concentrated in participants with elevated Lp(a), pointing to a specific, Lp(a)-mediated mechanism rather than a non-specific anti-inflammatory effect. These are observational findings and require confirmation in prospective trials, but the magnitude and consistency of effect are clinically significant.

Why Might Aspirin Work Selectively in High Lp(a) Individuals?

Aspirin's mechanism in this context is antiplatelet — not lipid-lowering. Lp(a) promotes platelet activation and hypo-fibrinolysis by inhibiting tissue-type plasminogen activator (tPA), while oxidized phospholipids drive valvular calcification through the p38 MAPK–NF-κB–BMP pathway. By interrupting platelet-mediated thrombosis, aspirin may attenuate Lp(a)-driven fibrocalcific deposition — particularly in early disease stages before irreversible valvular remodeling occurs. This mechanistic specificity explains why the MESA benefit appeared dose-dependent with Lp(a) thresholds rather than uniform across participants.[6,7]

 How Should Indian Clinicians Translate This Evidence Into Practice?

While international guidelines recognize Lp(a) ≥50 mg/dL as a risk-enhancing factor extending to valvular disease,[11] no guideline currently recommends aspirin specifically for CAVD prevention, and clinical decision-making must remain individualized. However, the following practice framework is practical and evidence-informed for the Indian context:

• Lp(a) Screening: Offer once-in-a-lifetime Lp(a) testing to adults >45 years with a family history of premature CAD, aligned with CSI/LAI recommendations. [2,9]

• Aspirin Consideration: May be considered in selected individuals with Lp(a) ≥50 mg/dL and 2–3 additional risk factors (elevated LDL-C, low HDL-C, diabetes, hypertension, CKD, smoking, family history of ASCVD, or CAC score >100) and low bleeding risk. Decision-making must weigh MESA's exploratory 2026 findings against established bleeding risk.[12]

• Comprehensive Risk Counseling: Address modifiable risk factors — blood pressure, cholesterol, diabetes, smoking — alongside Lp(a) burden. Explain the emerging role of aspirin in the context of degenerative calcific valvular disease in accessible terms.

Key Takeaways

• Degenerative aortic stenosis is rising earlier in India, compounded by high Lp(a) prevalence (25%) and pervasive dyslipidemia, creating a uniquely high-risk South Asian phenotype that demands proactive risk stratification. [1,2,3]

• Lp(a) is a causal, genetically determined, and non-modifiable driver of valvular calcification; the 2026 ACC/AHA and Indian (CSI/LAI) guidelines recommend at-least-once lifetime Lp(a) testing. [2,8,9]

• The 2026 MESA analysis shows aspirin may reduce Lp(a)-mediated aortic valve calcification by up to 83% (AVC) and 98% (severe AS) at high Lp(a) thresholds, a Lp(a)-dependent effect absent in low-Lp(a) individuals. [10]

• Aspirin use in this context should be individualized, balancing MESA's exploratory evidence against bleeding risk, in high-Lp(a) patients with additional CV risk factors and no contraindications. [6,7,10]

Abbreviations

AS = aortic stenosis; AVC = aortic valve calcium; BMP = bone morphogenetic protein; CAD = coronary artery disease; CAVD = calcific aortic valve disease; CSI = Cardiological Society of India; HDL-C = high-density lipoprotein cholesterol; HR = hazard ratio; LAI = Lipid Association of India; LDL-C = low-density lipoprotein cholesterol; Lp(a) = lipoprotein(a); MAPK = mitogen-activated protein kinase; MESA = Multi-Ethnic Study of Atherosclerosis; NF-κB = nuclear factor kappa B; OxPL = oxidized phospholipids; tPA = tissue-type plasminogen activator; CAC = coronary artery calcium; ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease; ACC = American College of Cardiology; AHA = American Heart Association